A priori inference of cross reactivity for drug-targeted kinases

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3092-3100

  Fernández, Ariel ^a   Maddipati, Sridhar ^b  

^a Rice University   (United States)

^b Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABELSON KINASE; FLT3 LIGAND; IMATINIB; PELITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; STAUROSPORINE; SUNITINIB; TIE 1 RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CROSS REACTION; DRUG BINDING SITE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; PROTEIN PHOSPHORYLATION; SPECTROPHOTOMETRY;

BINDING SITES; DRUG DESIGN; HUMANS; KINETICS; MODELS, MOLECULAR; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; STAUROSPORINE; SUBSTRATE SPECIFICITY;

EID: 33744800555     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060163j     Document Type: Article

References (29)

1. Taylor, S. S.; Radzio-Andzelm, E. Protein kinase inhibition: natural and synthetic variations on a theme. Curr. Opin. Chem. Biol. 1997, 1, 219-226.
2. Donato, N. J.; Talpaz, M. Clinical use of tyrosine kinase inhibitors: Therapy for chronic myelogenous leukemia and other cancers. Clin. Cancer Res. 2000, 6, 2965-66.
3. Dancey, J.; Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discovery 2003, 2, 296-313.
4. Fabbro, D.; Garcia-Echeverria C. G. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discovery Dev. 2002, 5, 701-712.
5. Gabriele, A.; King, G. L. Protein kinase C inhibitors in the treatment and prevention of diabetic complications. Curr. Opin. Endocrinol. Diabetes 2001, 8, 197-204.
6. Myers, M. R.; He, W.; Hulme, C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des. 1997, 3, 473-502.
7. Fabian, M. A. et al. A small molecule kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
8. Fernández, A.; Rogale, K.; Scott, R. L.; Scheraga, H. A. Inhibitor design by wrapping packing defects in HIV-1 proteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11640-11645.
9. Fernández, A.; Berry R. S. Molecular dimension explored in evolution to promote proteomic complexity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13460-13465.
10. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004, 1697, 243-257.
11. Fernández, A. Keeping dry and crossing membranes. Nat. Biotechnol. 2004, 22, 1081-1085.
12. Attoub, S.; Rival, C.; Rodrigues, S.; Van Borexlaer, S.; Bedin, M.; Buyneel, E.; Louvet, C., et al. The c-kit tyrosine kinase inhibitor STI-571 for colorectal cancer therapy. Cancer Res. 2002, 62, 4879-4883.
13. Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B. C.; Wilson, K. P. Structural basis for autoinhibition and STI-571 inhibition of C-kit Tyrosine kinase. J. Biol. Chem, 2004, 279, 31655-31663.
14. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.
15. Morin, M. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 2000, 19, 6574-6583.
16. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337.
17. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6, 1024.
18. Braken, C.; Iakoucheva, L. M.; Romero, P. R.; Dunker, A. K. Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol. 2004, 14, 570-576.
19. Couzin, J. Researchers puzzle over possible effect of Gleevec. Science 2005, 307, 1711
20. Fernández, A. Incomplete protein packing as a selectivity filter in drug design. Structure 2005, 13, 1829-1836
21. Link, J. T.; Raghavan, S.; Danishefsky, S. J. First total synthesis of staurosporine and ent-staurosporine. J. Am. Chem. Soc. 1995, 117, 552-553.
22. Bregman, H.; Williams, D. S.; Atilla, G. E.; Carroll, P. J.; Meggers, E. An organometallic inhibitor for glycogen synthase kinase 3. J. Am. Chem. Soc. 2004, 126, 13594-13595.
23. Knölker, H. J.; Reddy, K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev. 2002, 102, 4303-4427.
24. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
25. Cheng H. C.; Nishio H.; Hatase O.; Ralph S.; Wang J. H. A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of src-family tyrosine kinases. J. Biol. Chem. 1992, 267, 9248-56.
26. Brown N. R.; Noble M. E.; Endicott J. A.; Johnson L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell. Biol. 1999, 7, 438-43.
27. O'Neill T.; Giarratani L. et al. Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J. Biol. Chem. 2002, 277, 16102-15.
28. Le Good, J. A.; Ziegler, W. H.; Parekh, D. B.; Alessi, D. R.; Cohen, P.; Parker, P. J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998, 281, 2042-2045.
29. Hogue, C. W. V. Cn3D: a new generation of three-dimensional molecular structure viewer. Trends Biochem. Sci. 1997, 22, 314-316.